Skip to main content
main-content

Bone diseases

Osteoporosis

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

24-05-2019 | Rheumatoid arthritis | Highlight | News

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

25-04-2019 | Osteoporosis | News

No difference in fracture risk with denosumab vs alendronate

Patients initiating denosumab have a similar 3-year fracture risk to those initiating alendronate, regardless of sex, age, or fracture history, show results of a large study among Danish patients in routine clinical practice.

24-04-2019 | Osteoporosis | Highlight | News

Long-term drug treatment may reduce fracture risk in women with osteoporosis

Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

Long-term drug treatment may reduce fracture risk in women with osteoporosis

Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

11-04-2019 | Osteoporosis | News

FDA approves romosozumab for fracture prevention in osteoporosis

Click through for more information on this announcement

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

04-12-2018 | Comorbidities | Article

Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study

Panopoulos S et al. Arthritis Res Ther 2018. doi: 10.1186/s13075-018-1771-0

19-11-2018 | Osteoporosis | Article

Risk of subsequent fracture after prior fracture among older women

Balasubramanian A et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4732-1

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

27-10-2018 | Denosumab | ACR/ARHP 2018 | Video

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

24-10-2018 | Osteoporosis | ACR/ARHP 2018 | News

Two-year data support denosumab use in patients with glucocorticoid-induced osteoporosis

Greater increases in bone mineral density seen with denosumab versus risedronate in glucocorticoid-treated patients with osteoporosis are sustained through 24 months, indicate phase III data.

03-10-2018 | Osteoarthritis | News

Diabetes linked to elevated arthritis, osteoporosis risk

Patients with diabetes have an increased risk for arthritis, osteoporosis, and musculoskeletal pain, study findings indicate.

Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis

This systematic review and meta-analysis were performed with the aim to quantify the risk of hip fracture associated with proton pump inhibitor use [read more].
Hussain S et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4142-x

29-08-2018 | Osteoporosis | Review | Article

Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis

Hussain S et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4142-x

07-08-2018 | Rheumatoid arthritis | News

Disease activity linked to osteoporotic fracture risk in RA patients

Patients with rheumatoid arthritis who have high cumulative disease activity and functional disability have an elevated 10-year risk for osteoporotic fracture, researchers report.

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis

This study aimed to examine the relationship between medication persistence and fracture risk among female Medicare beneficiaries diagnosed with osteoporosis [read more].
Liu J et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4630-6

31-07-2018 | Osteoporosis | News

'Dismal' rates of osteoporosis treatment initiation after hip fracture

The proportion of patients initiating osteoporosis medication following hip fracture has declined in recent years, despite treatment reducing subsequent fracture risk, analysis of a US medical claims database suggests.

Image Credits